Patents Assigned to Arch Development
-
Patent number: 6524832Abstract: The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.Type: GrantFiled: August 19, 1994Date of Patent: February 25, 2003Assignee: Arch Development CorporationInventors: Donald Kufe, Ralph R. Weichselbaum
-
Patent number: 6511603Abstract: An extractant medium for extracting alkaline earth cations from an aqueous acidic sample solution is described as are a method and apparatus for using the same. The separation medium is free of diluent, free-flowing and particulate, and comprises a Crown ether that is a 4,4′(5′)[C4-C8-alkylcyclohexano]18-Crown-6 dispersed on an inert substrate material.Type: GrantFiled: October 24, 2000Date of Patent: January 28, 2003Assignee: Arch Development Corp.Inventors: Mark Dietz, E. Philip Horwitz
-
Patent number: 6511828Abstract: A new family of proteins having structural similarity to the baculovirus inhibitor of apoptosis protein (iap) are described. These ilp's (iap-like proteins) are distinguished by the presence of a RING finger domain and three baculovirus iap-like repeat motifs. Exemplified are sequences from Drosophila and human. Methods for the use of these proteins, and nucleic acids coding therefor, are provided. These methods include both the inhibition and stimulation of apoptosis in target cells.Type: GrantFiled: May 31, 1996Date of Patent: January 28, 2003Assignee: Arch Development CorporationInventors: Craig B. Thompson, Colin S. Duckett
-
Patent number: 6506378Abstract: The present invention provides methods and compositions for the therapeutic intervention of Parkinson's disease. More particularly, methods of making and sequestering dopamine are disclosed. Additionally, methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. Methods and compositions for carrying out such gene transfer and grafting are described.Type: GrantFiled: December 15, 1999Date of Patent: January 14, 2003Assignee: Arch Development CorporationInventor: Un Jung Kang
-
Publication number: 20020192822Abstract: The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an a4 gene, methods of inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.Type: ApplicationFiled: April 2, 2001Publication date: December 19, 2002Applicant: Arch Development CorporationInventors: Rosario Leopardi, Bernard Roizman
-
Patent number: 6488859Abstract: A cross-linked water-insoluble ion exchange resin comprised of polymerized monomers having a phenyl ring is disclosed. A contemplated resin contains (i) polymerized phenyl ring-containing monomers having a phosphonic acid ligand linked to the phenyl ring, (ii) about 2 to about 5 millimoles per gram (mmol/g) of phosphorus as phosphonic acid ligands, and (iii) a sufficient amount of a sulfonic acid ligand such that the ratio of mmol/g of phosphonic acid to mmol/g sulfonic acid is up to 3:1. A process for removing polyvalent metal cations from aqueous solution, and a process for removing iron(III) cations from acidic copper(II) cation-containing solutions that utilize the contemplated resin or other resins are disclosed.Type: GrantFiled: May 7, 2001Date of Patent: December 3, 2002Assignees: Arch Development Corp, The University of Tennessee Research CorpInventors: Spiro Alexandratos, Christopher A. Shelley, E. Philip Horwitz, Renato Chiarizia, Michael J. Gula, Sui Xue, James T. Harvey
-
Patent number: 6486170Abstract: A signaling pathway is identified that involves the activation of phospholipase A2 and protein kinase C in human cells, which in turn confers x-ray induction of the tumor necrosis factor &agr; (TNF) gene. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, as well as the subsequent activation of protein kinase C and TNF gene expression. These phospholipase A2 inhibitors may be used to ameliorate the adverse-effects of radiotherapy associated with TNF production.Type: GrantFiled: May 24, 1994Date of Patent: November 26, 2002Assignee: Arch Development CorporationInventors: Dennis E. Hallahan, Ralph R. Weichselbaum, Donald W. Kufe
-
Patent number: 6483934Abstract: A method, system, and computer product for the automated segmentation of the lung fields and costophrenic angle (CP) regions in posteroanterior (PA) chest radiographs, wherein image segmentation based on gray-level threshold analysis is performed by applying an iterative global gray-level thresholding method to a chest image based on the features of a global gray-level histogram. Features of the regions in a binary image constructed at each iteration are identified and analyzed to exclude regions external to the lung fields. The initial lung contours that result from this global process are used to facilitate a local gray-level thresholding method. Individual regions-of-interest (ROIs) are placed along the initial contour. A procedure is implemented to determine the gray-level thresholds to be applied to the pixels within the individual ROIs. The result is a binary image, from which final contours are constructed. Smoothing processes are applied, including a unique adaptation of a rolling ball method.Type: GrantFiled: April 27, 2001Date of Patent: November 19, 2002Assignee: Arch Development CorporationInventors: Samuel G. Armato, III, Maryellen L. Giger, Heber MacMahon
-
Patent number: 6482934Abstract: An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Novel amino acid sequences are shown for the amino-acid terminus and 6 interval fragments. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.Type: GrantFiled: March 28, 2000Date of Patent: November 19, 2002Assignee: ARCH Development Corp.Inventors: F. Gary Toback, John C. Lieske
-
Patent number: 6479628Abstract: Disclosed are purified and isolated DNA sequences encoding eukaryotic proteins possessing biological properties of inosine 5′-monophosphate dehydrogenase (“IMPDH”). Illustratively, mammalian (e.g., human) IMPDH-encoding DNA sequences are useful in transformation or transfection of host cells for the large scale recombinant production of the enzymatically active expression products and/or products (e.g., GMP) resulting from IMPDH catalyzed synthesis in cells. Vectors including IMPDH-encoding DNA sequences are useful in gene amplification procedures. Recombinant proteins and synthetic peptides provided by the invention are useful as immunological reagents and in the preparation of antibodies (including polyclonal and monoclonal antibodies) for quantitative detection of IMPDH.Type: GrantFiled: November 13, 2000Date of Patent: November 12, 2002Assignee: Arch Development CorporationInventors: Frank R. Collart, Eliezer Huberman
-
Patent number: 6472157Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.Type: GrantFiled: February 1, 2002Date of Patent: October 29, 2002Assignee: Arch Development CorporationInventors: Anna Di Rienzo, Lalitha Iyer, Mark J. Ratain
-
Patent number: 6470092Abstract: A method to determine whether a candidate abnormality in a medical digital image is an actual abnormality, a system which implements the method, and a computer readable medium which stores program steps to implement the method, wherein the method includes obtaining a medical digital image including a candidate abnormality; obtaining plural first templates and plural second templates respectively corresponding to predetermined abnormalities and predetermined non-abnormalities; comparing the candidate abnormality with the obtained first and second templates to derive cross-correlation values between the candidate abnormality and each of the obtained first and second templates; determining the largest cross-correlation value derived in the comparing step and whether the largest cross-correlation value is produced by comparing the candidate abnormality with the first templates or with the second templates; and determining the candidate abnormality to be an actual abnormality when the largest cross-correlation valType: GrantFiled: November 21, 2000Date of Patent: October 22, 2002Assignee: Arch Development CorporationInventors: Qiang Li, Shigehiko Katsuragawa, Kunio Doi
-
Patent number: 6467916Abstract: A non-imaging optical system for operating on light using broken symmetry reflector surfaces (30). The theoretical upper limit for concentration of direct solar radiation at low latitudes with stationary concentrators is determined from the projected solid angle sampled by the apparent motion of the sun. Based on the fact that the solar radiation is not uniformly distributed within this projected solid angle, we derive higher concentrations which apply when rejecting the lower density radiation. Trough type systems, which have translational symmetry, cannot be ideal stationary concentrators. Efficiency is improved by using broken symmetry for surfaces of the reflector (30) and the light source or concentrator. We note that what applies to concentrators applies equally to reflectors for illumination.Type: GrantFiled: June 6, 2001Date of Patent: October 22, 2002Assignee: Arch Development Corp.Inventor: Roland Winston
-
Patent number: 6466689Abstract: A system and method for digital imaging. A digital radiological image of a subject is obtained having at least one low density region. The image is processed using first weighting factors in the at least one low density region of the digital image and second weighting factors smaller than the first weighting factors in regions of the digital image other than the at least one low density region. A processed digital image is obtained and a representation of the processed digital image is produced. In the processing of the image, unsharp mask filtering is employed using a processing curve having maximum unsharp mask filtering in the at least one low density region of the digital image and a constant amount of unsharp mask filtering less than the maximum unsharp mask filtering in the regions of the image other than the low density regions.Type: GrantFiled: December 28, 1993Date of Patent: October 15, 2002Assignee: Arch Development Corp.Inventor: Heber MacMahon
-
Patent number: 6442287Abstract: An automated method, storage medium, and system for analyzing bone. Digital image data corresponding to an image of the bone are obtained. Next there is determined, based on the digital images, a measure of bone mineral density (BMD) and at least one of a measure of bone geometry, a Minkowski dimension, and a trabecular orientation. The strength of the bone is estimated based upon the measure of BMD and at least one of the measure of bone geometry, the Minkowski dimension, and the trabecular orientation. To improve bone texture analysis, the present invention also provides a novel automated method, storage medium, and system in which digital image data corresponding to an image of the bone is obtained, and a region of interest (ROI) is selected within the bone. A fractal characteristic of the image data within the ROI using an artificial neural network is extracted. The strength of the bone is estimated based at least in part on the extracted fractal characteristic.Type: GrantFiled: August 28, 1998Date of Patent: August 27, 2002Assignee: Arch Development CorporationInventors: Chunsheng Jiang, Michael R. Chinander, Maryellen L. Giger
-
Publication number: 20020115097Abstract: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.Type: ApplicationFiled: February 1, 2002Publication date: August 22, 2002Applicant: Arch Development CorporationInventors: Anna Di Rienzo, Lalitha Iyer, Mark J. Ratain
-
Patent number: 6436907Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus virus vector construct intravascularly.Type: GrantFiled: November 5, 1998Date of Patent: August 20, 2002Assignee: Arch Development CorporationInventors: Jeffrey M. Leiden, Eliav Barr
-
Patent number: 6436945Abstract: The present invention provides AGT inactivating compounds, for example, substituted O6-benzyl-8-aza-guanines of the formula wherein R, for example, is pivaloyloxymethyl as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of guanine.Type: GrantFiled: August 14, 2001Date of Patent: August 20, 2002Assignees: The United States of America as represented by the of Health and Human Services, The Penn State Research Foundation, Arch Development CorporationInventors: Robert C. Moschel, Anthony E. Pegg, M. Eileen Dolan, Mi-Young Chae
-
Patent number: 6429359Abstract: A genetic construct encoding a fusion protein including endogluconase E1 and a transit peptide is used to transform plants. The plants produce cellulase by expressing the genetic construct. The cellulase is targeted to plastids and can be collected and purified.Type: GrantFiled: September 2, 1999Date of Patent: August 6, 2002Assignee: ARCH Development CorporationInventor: Gayle Lamppa
-
Patent number: 6426351Abstract: Chelerythrine is an effective inhibitor of solid tumor growth and is extremely cytotoxic in combination with chemotherapeutic agents that directly damage DNA.Type: GrantFiled: August 11, 2000Date of Patent: July 30, 2002Assignees: Dana-Farber Cancer, Inc., Arch Development CorporationInventors: Ralph R. Weichselbaum, Donald W. Kufe, Steven J. Chmura, Mary E. Dolan